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Abstract
Colorectal cancer is a major cause of worldwide morbidity and mortality. As such,
there are many guidelines and recommendations set forth by various medical societ‐
ies regarding colonoscopy for screening and surveillance. The universal goal of these
guidelines is to reduce colorectal cancer prevalence and mortality. Recommendations
for colorectal cancer screening and surveillance using colonoscopy vary slightly be‐
tween medical society guidelines and are often dictated by some combination of age,
known disease severity, length of time since last study, family history, and comorbid
conditions.
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1. Introduction
Colorectal cancer is the second leading cause of death from cancer in the United States, as well
as the fourth most common cause of cancer-related death, and the third most diagnosed cancer
worldwide.[1, 3] In 2008, there were an estimated 1.2 million newly diagnosed cases of
colorectal cancer worldwide and an estimated 609,000 colorectal cancer-related deaths.[3] In
2014, it was estimated that there were 136,830 newly diagnosed cases of colorectal cancer and
nearly 50,310 deaths associated with this disease in the Unites States alone.[4] The age-adjusted
incidence of colorectal cancer in the United States was 43.7 cases per 100,000 population among
men and women based on reported cases from 2007 to 2011.[4] In 2011, there were an estimated
1,162,426 people living with colon and rectum cancer in the United States.[4] Screening of those
at average risk may result in lower mortality rates by detecting cancers at earlier and more
curable stages. Also, detection of cancer-precursor lesions may reduce the incidence of
colorectal cancer if removed on endoscopic screening tests.[5, 6] The incidence and mortality
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of colorectal cancer have declined from 2002 to 2010 in the United States,[7] possibly due to
improvement in the adherence to screening and surveillance guidelines.
2. Colorectal cancer screening
2.1. Prevention strategies
Recommended strategies for colorectal cancer screening can be divided into two categories:
stool tests (occult blood and DNA tests) and structural examinations (flexible sigmoidoscopy,
colonoscopy, double contrast barium enema, capsule endoscopy, and computed tomographic
colonography). Each screening method has its own advantages and disadvantages, which are
summarized in Table 1. Screening is currently recommended beginning at 50 years of age in
average-risk populations, and varies in populations with increased risks.[6, 8]
Test Advantages Disadvantages
Sensitive guaiac fecal occult
blood test
Inexpensive, easily done at home Low sensitivity, annually repeated,
lack of compliance
Fecal immunochemical test Inexpensive, easily done at home More expensive than guaiac fecal
occult, annually repeated, unknown
adherence, low sensitivity for
advanced adenomas
Stool DNA More accurate than blood detection;
easily done at home
Expensive, sensitivity and specificity
unknown, uncertain screening
intervals
CT Colonography High sensitivity of lesions >10 mm in
diameter; not invasive
Not been proven to reduce incidence or
mortality, bowel prep needed,
unknown management of polyps <6
mm in diameter, radiation exposure
Sigmoidoscopy Can be done in office without sedation,
60% reduction in mortality from cancer
of the distal colon
Proximal colon cancer may be missed
Colonoscopy 90% sensitivity for lesions >10 mm in
diameter, 53-72% reduction in
incidence and 31% reduction in
mortality from colorectal cancer,
lesions can be detected and removed
during one examination
Bowel preparation and expertise
needed, expensive, invasive with
possible complications
**Data from Lieberman[6], Baxter, et al.[9], Muller, et al.[10], and Singh, et al.[11]
Table 1. Advantages and disadvantages of screening tests
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Strategies used to identify patients at an increased risk for developing colorectal cancer should
be started early. Before determining the best screening tool, clinicians should determine a
patient’s level of risk. The most common indicator of increased risk is a first-degree relative
with colorectal cancer. Diagnosis of colorectal cancer in a first-degree relative before 50 years
of age is concerning for hereditary gastrointestinal cancer syndromes such as Lynch syndrome,
familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP),
and MUTYH-associated polyposis (MAP). Patients with hereditary gastrointestinal cancer
syndromes require a special timing for endoscopic screening and surveillance. Colonoscopy
is the preferred screening test in these persons, which should be initiated at 40 years of age or
10 years younger than the age at which the family member was diagnosed with colorectal
cancer, whichever comes first.[6, 8] Patients with chronic ulcerative colitis or colitis due to
Crohn’s disease are at increased risk for colorectal cancer and should undergo a screening
colonoscopy after 8-10 years.[6, 8] Prior colorectal cancer or polyps also increases the risk of
colorectal cancer, especially if polyps are large, or have villous architecture.[12]
2.2. Identifying high-risk individuals
The risk of developing colorectal cancer is largely multifactorial. The factors associated with
an increased risk of colorectal cancer include lack of physical activity, obesity, high-fat and
low-fiber diets, tobacco use, gender, ethnicity, and genetics. There is limited evidence to
suggest that lifestyle modification alone in adults will reduce the risk of this cancer.[6, 13]
Aspirin, nonsteroidal anti-inflammatory drugs, and hormone-replacement therapy can
decrease the risk of adenomas or colorectal cancer but are not recommended in prevention of
colorectal cancer because the possible adverse effects are higher than the potential benefits.[6,
14, 15]
2.3. Screening modalities
Multiple tests are used as options for colorectal cancer screening. Stool-based tests can improve
disease prognosis by detecting early cancers. Endoscopic or radiologic tests can visualize the
bowel mucosa and detect polyps that can be removed before malignant transformation.
Sensitivities of various screening modalities (Table 2) and screening guidelines (Table 3) can
be very useful when choosing the most appropriate screening test.
Test Sensitivity References
Cancer
Detection
Advanced
Adenoma*
Detection
Standard guaiac fecal occult
blood test
(three stool samples)
33-50% 11%
Mandel et al.[16],
Hardcastle et al.[17],
Kronborg et al.[18],
Imperiale TF.[19],
Ahlquist.[20]
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Test Sensitivity References
Sensitive guaiac fecal occult blood
test
(three stool samples)
50-75% 20-25%
Allison et al.[15], Levin
et al.[21], Whitlock et al.
[22], Ahlquist et al.[20]
Immunochemical fecal occult blood
test
(one-three stool samples)
60-85% 20-50% Levin et al.
[21],
Whitlock et al.[22]
Old stool DNA test
(one stool sample) 51% 18% Imperiale et al.
[19]
New stool DNA test
(one stool sample) ≥80% 40%
Allison et al.[15],
Itzkowitz et al.[23]
CT Colonography Uncertain;probably >90%
90% (if ≥10 mm
diameter) Johnson et al.
[24]
Sigmoidoscopy >95% (for distalcolon) 70%
Lieberman[6], Shelby et
al.[25]
Colonoscopy >95% 88-98%
Lieberman[6],
Imperiale et al.[19],
Schoenfeld et al.[26],
Lieberman et al.[27],
Pickhardt et al.[28],
Cotton et al.[29],
Rockey et al.[30]
*Advanced adenoma is defined as tubular adenoma that is ≥10 mm in diameter or with villous histologic features or high-
grade dysplasia.
Table 2. Sensitivity of one-time colorectal cancer screening tests
Screening Test ACS-MSTF-ACR USPSTF Recommended Interval forRescreening
Sensitive guaiac fecal occult
blood test
Recommended if "/>50%
sensitivity for colorectal
cancer
Recommended 1 yr
Fecal immunochemical test
Recommended if >50%
sensitivity for colorectal
cancer
Recommended; high-
sensitivity test only 1 yr
Stool DNA test
Recommended if >50%
sensitivity for colorectal
cancer
Not Recommended
(insufficient evidence to
assess sensitivity and
specificity of fecal DNA)
Uncertain
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Screening Test ACS-MSTF-ACR USPSTF Recommended Interval forRescreening
Flexible sigmoidoscopy
Recommended if
sigmoidoscope is inserted to
40 cm of the colon or to the
splenic flexure
Recommended; with guaiac
fecal occult blood test every 3
yr
5 yr
Barium enema Examination Recommended, but only ifother tests not available Not recommended 5 yr
CT colonography
Recommended, with referral
for colonoscopy if polyps ≥6
mm in diameter detected
Not recommended
(insufficient evidence to
determine risk-benefit ratio)
5 yr
Colonoscopy Recommended Recommended 10 yr
* Data from Lieberman[6], Preventive Services Task Force[14], Levin et al.[21], Preventive Services Task Force[14], and
Whitlock et al.[22]; ACS-MSTF-ACR denotes American cancer Society, US Multisociety task force on Colorectal Cancer,
and American College of Radiology; and USPSTF denotes US Preventive services Task Force.
Table 3. US colorectal cancer screening guidelines, 2008*
2.3.1. Fecal screening tests
Fecal screening tests use small stool samples to help determine the presence of colorectal
cancer. Fecal screening tests include Guaiac-based fecal occult blood test, immunochemical-
based fecal occult blood test, also known as fecal immunochemical test (FIT), and Cologuard
(fecal DNA testing, combined with hemoglobin and DNA methylation assays). These tests are
easily performed at home or in a clinical office, are noninvasive, inexpensive, without direct
adverse health effects, and require few specialized resources. One disadvantage of fecal testing
is that positive results require colonoscopy evaluation to confirm or exclude the diagnosis of
colorectal cancer.
Guaiac fecal occult blood tests detect hemoglobin peroxidase activity and turn guaiac-
impregnated paper blue, but are not specific for human blood. Three separate stool samples
per test are preferred for better sensitivity.[21] The fecal occult blood test is associated with
significant false-positive results, which may lead to unnecessary follow-up colonoscopies. In
the Minnesota trial, false-positive test results were found in almost 9% of fecal occult blood
testing.[3] The cost-effectiveness of colorectal cancer screening with an annual or biennial fecal
occult blood test varied from US$ 5,691 to US$ 17,805 per life-year gained.[31] Randomized,
controlled trials in which standard guaiac tests were administered annually or biennially have
shown that cancers are detected at an earlier and more curable stage when compared with no
regular screening. Over a period of 10-13 years, regular guaiac screening tests result in a
reduction of colorectal cancer mortality by 15-33%.[6, 8, 32]
FIT uses antibodies specific to hemoglobin to screen for colorectal cancer. It is more accurate
than the guaiac test.[33, 37] As a result, FIT is now recommended as the first-choice fecal occult
blood test in colorectal cancer screening.[38] FIT has sensitivity for detecting cancer of 60-85%
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with the use of one to three stool samples.[4, 6, 22] Cologuard is a screening modality that tests
stool DNA for specific mutations that are associated with colorectal cancer. These specific
segments of cellular DNA are excreted in stool and can be detected with the use of polymerase
chain reaction (PCR) amplification. Newer versions of the test are currently being developed;
however, overall performance, utility, and cost-effectiveness has not been well studied.
2.3.2. Structural examinations of the colon
Colorectal cancers can be detected through physical exams with a digital rectal examination,
but there is little evidence to support the effectiveness of digital rectal exam in the detection
of colorectal cancer and, therefore, it is not recommended in the current screening guidelines
(Table 3).
Anatomical examination of the colon is effective in detection of early cancer and precancerous
lesions. Radiography imaging such as barium enema and computed tomographic (CT)
colonography can be used to detect lesions. In clinical studies of CT colonography for polyp
detection with expert radiologists, 90% of polyps 10 mm or larger in diameter were identified
correctly, with a false-positive rate of 14%.[6] CT colonography is not as sensitive for polyps
less than 6 mm. There are currently no conclusive studies supporting appropriate screening
intervals for negative results or suitable next steps for polyps less than 6 mm. While radiation
exposure during CT colonography is considered minimal, the cumulative radiation exposure
puts people at increased risk for developing other types of radiation-related cancers. Addi‐
tionally, cost-effectiveness of CT colonography has not been thoroughly studied in comparison
to other modalities.
Before colonoscopy became available, barium enema was the primary means of detecting
polyps, and their removal required surgical colostomy.[39] Barium enema examination is not
the best test for identifying precancerous lesions and is rarely used for colorectal-cancer
screening in current practice.[6] Double-contrast barium enema is another screening modality
that involves the patient drinking contrast, which coats the intestinal mucosa with barium.
Then, the colon is insufflated with air and multiple radiographs are taken under fluoroscopy.
Double-contrast barium enema detects about half of adenomas larger than 1 cm and 39% of
all polyps.[40] Retrospective studies have found that double-contrast barium enema failed to
diagnose 15-22% of colorectal cancers.[41] If an abnormality is found, then colonoscopy
evaluation should follow. False-positives or inconclusive results can be a result of stool,
mucosal irregularities, or air. Barium enemas are safe and typically do not require sedation,
but may cause the patient discomfort during the procedure. The usage rates of double contrast
barium enema for colorectal cancer screening recently declined with improved screening tools,
but may be useful where colonoscopy is not readily available.[42]
Endoscopic screening is more sensitive than fecal testing for the detection of adenomatous
polyps.[37, 43, 45] In the United Kingdom, one-time screening with flexible sigmoidoscopy
significantly reduced the incidence of colorectal cancer by 23% and cancer-related mortality
by 31%.[45, 46] Studies, with the use of screening colonoscopy, have shown that more than
30% of patients with advanced neoplasia have proximal lesions that would not be identified
with sigmoidoscopy alone.[47, 48]
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The most performed indication for colonoscopy in the United States is for screening and
surveillance purposes. Colonoscopy can detect a wide range of colon pathologies including
polyps, angiodysplasias, hemorrhoids, and cancer. Colonoscopy also permits therapeutic
interventions. The procedure is highly feasible and relatively safe. The quality of the procedure
depends on an adequate bowel preparation. The patient is typically sedated throughout the
procedure. Colonoscopy can reduce the incidence and the mortality of colorectal cancer.[9, 27,
49] Endoscopic procedures may be uncomfortable for patients and carry the risks of perfora‐
tion and bleeding, especially when polypectomy is performed. The risk of serious adverse
events is 3-5 events per 1000 colonoscopies.[6]
Capsule endoscopy has the potential to become a useful screening tool. A camera, in the size
and shape of a pill, is swallowed to help visualize the gastrointestinal tract. Reductions of
incidence and mortality have not yet been studied using this modality. Capsule endoscopy
does not require sedation or radiation. However, accuracy data show inferior screening
performance compared to colonoscopy.[3] Despite all these available methods, colorectal
cancer screening rates are still suboptimal. In a National Health Interview Survey in 2010, the
rate of screening was only 58.6%.[39]
2.4. Screening guidelines
Two major guidelines, from the US Preventive Services Task Force (USPSTF) and a joint
guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal
Cancer, and the American College of Radiology (ACS-MSTF), were released in 2008 regarding
colorectal cancer screening in the United States (Table 3). The joint guidelines recommend
structural examinations for cancer prevention. The ACS-MSTF recommends offering screening
beginning at age 50 years for average-risk patients, and continued surveillance every 10 years,
if negative. In average-risk patients, CT colonography should be performed every 5 years,
flexible sigmoidoscopy every 5 years, and double-contrast barium enema every 5 years. The
joint guidelines recommend fecal occult blood testing with sensitive guaiac method or fecal
immunochemical-based test every year for screening. Screening should be terminated if a
patient’s life expectancy is less than 10 years.[21] Prior to screening, patients should under‐
stand that a positive test indicates a need for colonoscopy. There are no specific guidelines
regarding colorectal cancer screening for sex or ethnicity but the American College of Gastro‐
enterology supports initiation of screening in African Americans at 45 years of age.[8]
The US Preventive Services Task Force does not recommend CT colonography or stool DNA
testing. The USPSTF recommends three screening options for adults 50-75 years old: sensitive
fecal occult blood testing annually, flexible sigmoidoscopy every 5 years with sensitive fecal
occult blood test every 3 years, and colonoscopy every 10 years. Screening for patients older
than 75 is not routinely recommended by the USPSTF, and recommends against screening over
the age of 85 years.[14] Colorectal cancer screening in older patients who have never undergone
formal screening is controversial and there are currently no guidelines regarding appropriate
screening in these scenarios. The risk of colorectal cancer and advanced polyps continues to
increase in age even after 75 years. Thus, the decision to screen between the ages of 75 and 85
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years should be discussed with and individualized to each patient depending on health status
and other comorbidities.
In Europe, fecal occult blood testing is implemented at higher rates than in the United States.
The fecal occult blood test for individuals aged 50-74 years at average-risk has been recom‐
mended to date by the European Union guidelines for colorectal screening, annually or
biennially.[15]
The British Society of Gastroenterology (BSG) and the Association of Coloproctology for Great
Britain and Ireland (ACPGBI) aimed to provide guidance on the appropriateness, method, and
frequency of screening for people at moderate- and high-risk for colorectal cancer.[50]
3. Colorectal cancer surveillance
Surveillance colonoscopy refers to colonoscopy examination performed in asymptomatic
individuals with previously identified cancerous or precancerous lesions. Colonoscopy
surveillance is used to identify any recurrent or new neoplasia in these individuals.[51] High
adenoma detection rate on follow-up colonoscopy (30-50%) provides the rationale for surveil‐
lance colonoscopy.[52, 56] There is strong evidence that surveillance colonoscopy decreases
colorectal cancer incidence and colorectal cancer-related mortality.[57]
The timing of subsequent surveillance is crucial. Studies demonstrate both the protective effect
and cost-effectiveness of performing surveillance colonoscopy on high-risk populations.[58]
The overall impact of surveillance is not well defined and may be decreased by an inappro‐
priate utilization of resources and nonadherence to published guidelines.[59]
3.1. Recommendations for surveillance colonoscopy
Guidelines from Gastrointestinal societies in the United States, the United Kingdom, and the
European Union follow a risk stratification policy to time their surveillance intervals.
The US Multisociety Task Force (US MSTF) guidelines were published in 2008 and categorize
patients into two major risk groups based on the likelihood of development of advanced
neoplasia (Table 4). In 2012, the US MSFT updated their guidelines to address the role of
serrated polyps, risk of interval colorectal cancer, and proximal colorectal cancer (Table 5).
The European Society of Gastrointestinal Endoscopy (ESGE) updated their guidelines in 2013
and formulated a risk stratification and surveillance strategy similar to the United States (Table
4 and Table 5). A new recommendation was to increase the interval from 3 years to 5 years
after a normal follow-up colonoscopy in the high-risk group (3-4 adenomas, villous features
or high-grade dysplasia, or ≥10 mm in size).
The UK guidelines are based on adenoma size and number without incorporating histological
findings. It stratifies patients into low-, moderate-, and high-risks groups. It also recommends
a “single clearing examination” at 1 year for high-risk patients (≥5 small adenomas or ≥3
adenomas, at least 1 of which is ≥1 cm).
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United States Multisociety
Task Force (US MSTF)
European Society of
Gastrointestinal Endoscopy
(ESGE)
British Society of
Gastroenterology (BSG)
Risk
Low 5-10 years 10 years No surveillance or 5 years
Moderate - - 3 years
High 3 years 3 years 1 years
Table 5. Surveillance interval recommendation
A recently published study, which analyzed 3226 post-polypectomy patients, compared the
US MSTF guidelines with the British Society of Gastroenterology (BSG) guidelines. The study
showed that the application of the UK guidelines into the US population reclassified 26.3% of
patients from high-risk to a higher-risk category and 7% to a lower-risk category.[60] The study
also showed a net 19% of patients benefiting from detection 2 years earlier without substan‐
tially increasing rates of colonoscopy.[60]
3.2. Sessile serrated adenomas/polyps and surveillance colonoscopy
Sessile serrated adenoma/polyp (SSA/P) is a term used to describe polyps or adenomas
characterized by the presence of a sawtooth appearance to crypt contour with prominent
dilatation, serrations, and lateralization at the crypt base.[51] The discovery of the serrated
adenoma/polyp pathway and the development of colorectal cancer has led to increased interest
United States Multisociety
Task Force (US MSTF)
European Society of
Gastrointestinal Endoscopy
(ESGE)
British Society of
Gastroenterology (BSG)
Risk
Low 1-2 tubular adenomas <10 mm
1–2 tubular adenomas <10 mm
with low-grade dysplasia;
serrated polyps < 10 mm and no
dysplasia
1–2 adenomas <10 mm
Moderate - - 3–4 adenomas <10 mm or at leastone adenoma >1cm
High
Adenoma with villous
histology or high-grade
dysplasia or ≥10 mm or ≥3
adenomas
Adenoma with villous histology
or high-grade dysplasia or ≥ 10
mm in size, or ≥3 adenomas;
serrated polyps ≥ 10 mm or with
dysplasia
>5 small adenomas or at least 3
adenomas >1cm
Table 4. Risk stratification criteria
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and focus on the understanding of the histological and molecular changes that lead to CRC.
Hypermethylation of genes in serrated lesions leads to microsatellite instability and rapid
development of colorectal cancer.[61]
Endoscopically, serrated lesions have a similar appearance to hyperplastic polyps and are often
misdiagnosed as such. A recent study showed that as high as one-third of recently diagnosed
hyperplastic polyps ≥5 mm were reclassified into SSA/P after a second pathology review.[62]
The CARE study found that serrated lesions were five times more likely to be incompletely
resected by polypectomy compared to conventional adenomas.[63] Serrated polyps larger than
1 cm or with a dysplastic component are considered advanced polyps.[63]
Surveillance recommendations for serrated adenomas/polyps are inconsistent among re‐
searchers and gastrointestinal societies and long-term studies evaluating SSA/P are limited.
US MSTF and ESGE classifies serrated polyps <10 mm with no dysplasia as low-risk and
serrated polyps ≥10 mm or those with dysplasia as high-risk. Both societies recommend
surveillance colonoscopy in 3 years in high-risk. For low-risk lesions, ESGE recommends 10-
year follow-up, whereas US MSTF recommends 5-year follow-up.[14, 50, 64]
3.3. Serrated polyposis syndrome
The World Health Organization defines serrated polyposis syndrome by either the presence
of five or more serrated polyps proximal to the sigmoid colon (at least two of which must be
≥10 mm) or 20 or more serrated polyps of any size distributed throughout the colon.[65] US
MSFT and ESGE recommend one-year follow-up surveillance in this patient population. [14,
66] ESGE also recommends referral for genetic counseling.[14, 66]
3.4. Effect of positive family history on surveillance intervals
Patients with a family history of colorectal carcinoma are at higher risk of developing high-
risk adenoma and colorectal carcinoma. US MSTF recommends shortening the surveillance
interval from 10 years to 5 years in patients with low-risk findings on colonoscopy and a first-
degree relative with colorectal cancer prior to the age of 60.[14] US MSTF also recommends
surveillance with colonoscopy as the preferred method.[14]
3.5. Surveillance colonoscopy in the elderly
There is a significant increase in incidence of both CRC and adenomas with increasing age.[14]
The age at which screening colonoscopy should be performed remains controversial. Studies
that examined the role of age in surveillance colonoscopy found no association with increasing
age and polyp recurrence and concluded it was not necessary to tailor surveillance guidelines
by age.[5, 67, 70] Retrospective studies have also shown that comorbidities reduce the benefits
of CRC screening. The US MSTF does not give a specific age at which screening can be ceased,
but recommends that competing comorbidities and life expectancy should be considered
before ordering cancer screening at any age.[14]
Screening for Colorectal Cancer with Colonoscopy24
3.6. Surveillance colonoscopy and physician nonadherence to guidelines
Nonadherence to guidelines remains a major problem in healthcare policy. The overuse of
resources could lead to increased demand for colonoscopy, shifting resources from screening,
and thus decreasing the cost-effectiveness of CRC screening program by increasing the
unnecessary costs and possibility of adverse events. Alternatively, underuse of colonoscopy
in surveillance may lead to suboptimal prevention of colorectal cancer. Schohen, et al.
retrospectively evaluated 3,627 screening patients with a history of adenoma removal and
found overuse of endoscopy in low-risk patients and underuse in high-risk patients.[71] The
reasons for guideline nonadherence include lack of strong evidence to support the surveillance
intervals, having multiple guidelines with inconsistent recommendations, lack of awareness
of current evidence, fear of legal implication, suboptimal bowel preparation, financial incen‐
tive for performing the procedure, and miscommunication between gastroenterologist and
primary care providers.[72] Measures to improve adherence to guidelines include continued
medical education; written recommendations by endoscopist regarding the follow-up interval
after the pathology report; quality improvement interventions such as reminder devices;
improvement of bowel preparation quality; automated electronic alerting system[72, 73]; and
continuous quality improvement process for colonoscopy (education, monitoring, audits, and
financial incentives/penalties).[74]
4. Conclusion
Colorectal cancer screening and surveillance have been shown to provide many benefits. The
associated risks are relatively minor and vary greatly on the particular screening test, and
surveillance regimen. Patients should be informed that screening and surveillance reduce the
risk of colorectal cancer, but may require additional tests and/or procedures to diagnose and
manage the pathologic findings. Colorectal cancer screening rate is still suboptimal in the
United States and this rate could be improved by dedicated patients and clinician reminders,
patients’ education, outreach, and follow-up. Screening and surveillance must be targeted to
appropriate patients and occur at recommended intervals to ensure proper prevention.
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